SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high risk neuroblastoma: A Children's Oncology Group study. J Clin Oncol. 2011; 29: 43514357.
  • 2
    Saylors RL 3r d, Stine KC, Sullivan J, et al. Pediatric Oncology Group. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001; 19: 34633469.
  • 3
    Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006; 24: 52715276.
  • 4
    Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol. 2009; 27: 12901296.
  • 5
    Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003; 98: 24882494.
  • 6
    Simon T, Langler A, Berthold F, Klingebiel T, Hero B. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol. 2007; 29: 101106.
  • 7
    Simon T, Langler A, Harnischmacher U, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma: results of a phase-II trial. J Cancer Res Clin Oncol. 2007; 133: 653661.
  • 8
    Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res. 2004; 10( 1 pt 1): 8487.
  • 9
    Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010; 116: 30543060.
  • 10
    Kushner BH, Kramer K, Modak S, Yataghene K, Cheung NK. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. Eur J Cancer. 2010; 47: 8489.
  • 11
    Kushner BH, Kramer K, Modak S, Cheung NK. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer. 2011; 56: 403408.
  • 12
    Frappaz D, Michon J, Hartmann O, et al. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol. 1992; 10: 15921601.
  • 13
    Alvarado CS, Kretschmar C, Joshi VV, et al. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG phase II study. J Pediatr Hematol Oncol. 1997; 19: 6267.
  • 14
    Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. Cancer. 1993; 71: 18981903.
  • 15
    Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995; 13: 16001608.
  • 16
    Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose-response and schedule dependence. J Clin Oncol. 1997; 15: 23782384.
  • 17
    Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11: 14661477.
  • 18
    Marina NM, Rodman JH, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993; 11: 554560.
  • 19
    Marina NM, Rodman JH, Murry DJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J Natl Cancer Inst. 1994; 86: 544548.
  • 20
    Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group phase I/II study. J Pediatr Hematol Oncol. 1995; 17: 265269.
  • 21
    Pratt CB, Luo X, Fang L, Marina N, Avery L, Furman WL. Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience. Med Pediatr Oncol. 1996; 27: 145148.
  • 22
    Marina NM, Shema SJ, Bowman LC, et al. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol. 1994; 23: 328334.
  • 23
    Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 2001; 92: 914923.
  • 24
    Cairo M, Krailo M, Weinthal J, et al. A phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors. Cancer. 1998; 83: 14491460.
  • 25
    Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between 2 doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a Children's Cancer Group report. J Pediatr Hematol Oncol. 2001; 23: 3038.
  • 26
    Bracho F, Krailo MD, Shen V, et al. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Clin Cancer Res. 2001; 7: 5867.
  • 27
    Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005; 44: 338347.
  • 28
    Abdel Rahman H, Moussa EA, Zekri WZ, et al. Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma? J Egypt Natl Cance Inst. 2011; 23: 4753.
  • 29
    Donfrancesco A, Jenkner A, Castellano A, et al. Ifosfamide/carboploatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over 1 year of age. Acta Paediatr Suppl. 2004; 93: 611.
  • 30
    Sung KW, Lee SH, Yoo KH, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant. 2007; 40: 3745.
  • 31
    De Ioris MA, Castellano A, Llari I, et al. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur J Cancer. 2011; 47: 572578.
  • 32
    Kreissman SG, Rackoff W, Lee M, Breitfeld PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol. 1997; 19: 309312.
  • 33
    Meresse V, Vassal G, Michon J, et al. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1993; 11: 630637.
  • 34
    Phillip T, Ghalie R, Pinkerton R, et al. A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1987; 5: 941950.
  • 35
    Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007; 19: 108-114.
  • 36
    Hawkins DS, Felgenhauer J, Park J, et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer. 2002; 95: 13541365.
  • 37
    Pradhan KR, Johnson CS, Vik TA, Sender LS, Kreissman SG. A novel induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer. 2006; 46: 793802.
  • 38
    Grupp SA, Cohn SL, Wall D, Reynolds CP; Hematopoietic Stem Cell Transplant Discipline and the Neuroblastoma Disease Committee, Children's Oncology Group. Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day. Pediatr Blood Cancer. 2006; 46: 719722.
  • 39
    Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009; 27: 10201025.
  • 40
    Bensimhon P, Villablanca JG, Sender LS, et al. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010; 54: 596602.
  • 41
    Strather D, Ashley D, Kellie SJ, et al. Feasibility of 4 consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol. 2001; 19: 26962704.